SCHEMBL6704698

SCHEMBL6704698

COC(=O)c1cccc(Cl)c1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.49
CFTR P13569 1/20 0.47
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 2/20 0.44
MAPK14 Q16539 1/20 0.44
ADAMTS7 Q9UKP4 1/20 0.44
PDK2 Q15119 3/20 0.44
KDM4E B2RXH2 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PDK1 Q15118 1/20 0.42
PDK3 Q15120 1/20 0.42
PDK4 Q16654 1/20 0.42
KCNJ5 P48544 1/20 0.42
KCNJ3 P48549 1/20 0.42
NR4A2 P43354 2/20 0.42
RORC P51449 1/20 0.41
RORB Q92753 1/20 0.41
P2RX1 P51575 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4203346 0.84 MTTP (0.52) CFTRPDK2TRPV1
SCHEMBL6705895 0.84 CFTR (0.48) MRGPRX4CFTRSLC6A4SLC6A3ADAMTS7
SCHEMBL6697416 0.83 ITGB1 (0.49) MRGPRX4CFTRSLC6A4SLC6A3ADAMTS7
SCHEMBL7642362 0.82 SLC6A4 (0.49) CFTRSLC6A4SLC6A3NR4A2
SCHEMBL5099992 0.82 FABP4 (0.49) MRGPRX4ADAMTS7KCNJ5KCNJ3RORC
SCHEMBL7638449 0.82 FABP4 (0.55) CFTRSLC6A4SLC6A3KDM4ENR4A2
SCHEMBL6704771 0.81 CFTR (0.45) MRGPRX4CFTRSLC6A4SLC6A3PDK2
SCHEMBL6706499 0.80 ALDH1A1 (0.48) SLC6A4SLC6A3KDM4ENR4A2
SCHEMBL6798068 0.79 P2RX1 (0.46) CFTRPDK2TRPV1P2RX1
SCHEMBL29979725 0.77 SLC6A3 (0.69) CFTRSLC6A4SLC6A3PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors SMITHKLINE BEECHAM CORPORATION 2004-02-05 US disclosed
EP-1289971-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS GLAXO GROUP LIMITED (GB) 2003-03-12 EP disclosed
WO-2001092241-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS GLAXO GROUP LIMITED (GB) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024215-A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors APOB, APOL1, CETP MRGPRX4 1792/4885CFTR 1451/4885SLC6A4 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.